• In April 2026, Abbott Laboratories reported late-breaking data from four trials in its pulsed field ablation and conduction system pacing portfolios, highlighting strong safety and clinical outcomes for treating complex atrial fibrillation and other heart rhythm disorders across devices such as the TactiFlex Duo catheter and Volt PFA System.
• A distinctive feature of these results is the high proportion of complex AFib cases successfully treated using pulsed field ablation alone, reinforcing Abbott’s positioning in next-generation cardiac rhythm management technologies.
• Next, we’ll examine how this new evidence for pulsed field ablation and conduction system pacing could influence Abbott’s broader investment narrative.

Capitalize on the AI infrastructure supercycle with our selection of the 38 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Abbott Laboratories Investment Narrative Recap

To own Abbott, I think you need to believe its diversified healthcare portfolio and innovation in devices, diagnostics, and nutrition can offset pressures in slower areas like COVID-related testing and certain diagnostics markets. The latest pulsed field ablation and conduction system pacing data strengthens the case for Abbott’s cardiac rhythm management pipeline, but it does not fundamentally change the near term focus on execution in diagnostics and pricing risks in diabetes care.

Among recent announcements, the first quarter 2026 results are most relevant, because they show sales growth alongside lower net income and earnings per share. Against that backdrop, the new AFib and pacing trial readouts sit within a broader device pipeline story that many investors view as a key offset to margin pressures from tariffs, foreign exchange, and competitive bidding in core testing and diabetes technologies.

Yet despite these device advances, investors still need to weigh the risk that competitive bidding and pricing pressure in continuous glucose monitoring could...

Abbott Laboratories’ narrative projects $59.7 billion revenue and $9.5 billion earnings by 2029. This requires 9.8% yearly revenue growth and about a $3.2 billion earnings increase from $6.3 billion today.

Uncover how Abbott Laboratories' forecasts yield a $118.64 fair value, a 28% upside to its current price.

Exploring Other Perspectives

Five members of the Simply Wall St Community currently place Abbott’s fair value between US$118.64 and about US$132.00, reflecting a relatively tight cluster of views. You should weigh those opinions against the risk that intensifying competition and pricing pressure in US glucose monitoring could affect Abbott’s ability to sustain the broader earnings profile many investors are counting on.

Explore 5 other fair value estimates on Abbott Laboratories - why the stock might be worth just $118.64!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Abbott Laboratories research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Abbott Laboratories research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Abbott Laboratories' overall financial health at a glance.

Ready For A Different Approach?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• AI is about to change healthcare. These 32 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Uncover the next big thing with 24 elite penny stocks that balance risk and reward.
• We've uncovered the 13 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.